KRAS and myeloproliferative neoplasm: Interestingly, it has even been reported that some patients with somatic NRAS (especially the NRASG12S) (40) and KRAS (especially the KRASG12V) (41) mutations, may have an indolent course or even spontaneously regress their MPN.